Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2013. She is based in London, UK.
Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline.
In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan.
In 2012, upon the establishment of the Innovation Centers, Dr Bolger joined J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. She is based in London with responsibility for investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer.
Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Asceneuron, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, and S-Biomedic